Publikationen, an denen er mitarbeitet Atanasio Pandiella Alonso (24)

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2014

  1. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2013

  1. RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications

    Investigational New Drugs, Vol. 31, Núm. 1, pp. 200-205

  2. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

    Leukemia, Vol. 27, Núm. 2, pp. 430-440

2012

  1. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

    Haematologica, Vol. 97, Núm. 7, pp. 1110-1114

  2. Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects

    PLoS ONE, Vol. 7, Núm. 4

2011

  1. Deficient spindle assembly checkpoint in multiple myeloma

    PLoS ONE, Vol. 6, Núm. 11

  2. Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response

    Haematologica, Vol. 96, Núm. 5, pp. 687-695

2010

  1. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

    Haematologica, Vol. 95, Núm. 5, pp. 794-803

2009

  1. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

    Leukemia, Vol. 23, Núm. 8, pp. 1515-1527

  2. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

    Leukemia, Vol. 23, Núm. 12, pp. 2265-2274

  3. Zalypsis: A novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

    Blood, Vol. 113, Núm. 16, pp. 3781-3791

2008

  1. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo

    Cancer Research, Vol. 68, Núm. 13, pp. 5216-5225

  2. Expression of c-Kit isoforms in multiple myeloma: Differences in signaling and drug sensitivity

    Haematologica, Vol. 93, Núm. 6, pp. 851-859

  3. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

    The Lancet Oncology, Vol. 9, Núm. 12, pp. 1157-1165

  4. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype

    Haematologica, Vol. 93, Núm. 1, pp. 57-66

  5. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells

    British Journal of Haematology, Vol. 141, Núm. 4, pp. 470-482

2007

  1. Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis

    Leukemia, Vol. 21, Núm. 4, pp. 797-804

2006

  1. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

    Blood, Vol. 107, Núm. 9, pp. 3575-3583

  2. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance

    Cancer Research, Vol. 66, Núm. 11, pp. 5781-5789